false
OasisLMS
Catalog
Modern Lipid Management: The Updated Medicine Cabi ...
Novel and Emerging Therapies: Inclisiran
Novel and Emerging Therapies: Inclisiran
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The video is a presentation about a new therapy called inclisiran, which is a cholesterol-lowering agent in the siRNA class. The presenter explains that inclisiran works by inhibiting PCSK9, a protein that degrades LDL receptors, allowing LDL and the receptor to interact normally and reduce LDL levels. The presenter mentions that current PCSK9 inhibitors have low uptake due to cost and inconvenience. However, inclisiran offers a potential solution with twice-yearly injections providing durable and sustained LDL reduction of over 50%. The therapy has shown promising results in preclinical and clinical studies, and the presenter suggests that inclisiran could be an additional option for patients with atherosclerotic cardiovascular disease.
Keywords
inclisiran
cholesterol-lowering agent
siRNA class
PCSK9 inhibitor
LDL reduction
×
Please select your language
1
English